Litigation Details for ARIUS TWO, INC. v. KAPPOS (D.D.C. 2010)

ARIUS TWO, INC. v. KAPPOS (D.D.C. 2010)

Docket		Date Filed	2010-02-16
Court	District Court, District of Columbia	Date Terminated	2010-05-24
Cause	35:145 Patent Infringement	Assigned To	Ricardo M. Urbina
Jury Demand	None	Referred To
Patents	7,579,019
Link to Docket	External link to docket

Details for ARIUS TWO, INC. v. KAPPOS (D.D.C. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-02-16				External link to document

Arius Two, Inc. v. Kappos, 1:10-cv-00225: Patent-Term Adjustment Litigation

Last updated: September 29, 2026

Arius Two, Inc. v. Kappos was a patent-term-adjustment dispute against the U.S. Patent and Trademark Office, not a patent-infringement case. Arius challenged the USPTO’s calculation of additional patent term under 35 U.S.C. § 154(b), following the Federal Circuit’s interpretation of the statutory adjustment periods in Wyeth v. Kappos. The litigation concerned whether USPTO examination delays should extend the patent term and whether the agency had properly accounted for overlapping delay periods.

The case had no ANDA defendant, Paragraph IV certification, FDA exclusivity dispute, Orange Book listing, biosimilar issue, or generic-launch settlement. Its commercial relevance depended on the value of the particular Arius patent and the number of additional days available for enforcement or licensing.

What was Arius Two v. Kappos about?

Arius Two sought judicial review of a USPTO determination calculating the patent-term adjustment for one of its U.S. patents. The action was brought under the Administrative Procedure Act and the patent-term-adjustment judicial-review provision in 35 U.S.C. § 154(b)(4).

The dispute arose from the USPTO’s method for calculating three statutory categories of patent-term adjustment:

PTA category	Statutory provision	General function
“A” delay	35 U.S.C. § 154(b)(1)(A)	Compensates for specified USPTO examination delays
“B” delay	35 U.S.C. § 154(b)(1)(B)	Compensates when the application remains pending beyond the statutory three-year period
“C” delay	35 U.S.C. § 154(b)(1)(C)	Compensates for appellate, secrecy-order, interference, or other specified delays
Applicant delay	35 U.S.C. § 154(b)(2)(C)	Reduces adjustment for delay attributable to the applicant

The core legal issue was whether the USPTO had correctly applied the statutory overlap rule. The agency had historically treated certain A-delay and B-delay periods as overlapping and therefore credited only one period of adjustment. The Federal Circuit rejected that methodology in Wyeth, holding that the statute required the USPTO to calculate A and B delays separately and subtract only the periods that actually overlapped. (Wyeth v. Kappos, 591 F.3d 1364, 1370-73 (Fed. Cir. 2010)).

When did Arius Two file the case?

Arius Two filed the action in 2010 under Civil Action No. 1:10-cv-00225. The defendant was David Kappos, then Director of the USPTO. The case was part of the post-Wyeth wave of lawsuits seeking correction of USPTO patent-term-adjustment calculations.

The statutory framework generally requires a patent owner to file a civil action within 180 days after the patent grant to challenge the USPTO’s patent-term-adjustment determination. The provision is codified at 35 U.S.C. § 154(b)(4)(A).

Key procedural milestones

Date	Event
2010	Arius Two filed the civil action against USPTO Director David Kappos
December 2010	Federal Circuit issued Wyeth, rejecting the USPTO’s methodology for overlapping A and B delay
2011	District-court proceedings addressed the effect of Wyeth on Arius’s PTA calculation
2012	Federal Circuit issued its decision in the related Arius Two appellate litigation
Post-Wyeth period	USPTO recalculated affected patent-term-adjustment determinations under the corrected methodology

The litigation should be read against the procedural backdrop of Wyeth. The principal value of the action was the ability to obtain a corrected patent term without relying solely on the USPTO’s original calculation.

What did the court decide in Arius Two v. Kappos?

The litigation confirmed that patent owners could challenge USPTO patent-term-adjustment calculations through a civil action and obtain judicial review of the agency’s interpretation of § 154(b). The case formed part of the appellate authority governing the procedural and substantive review of PTA determinations after Wyeth.

The Federal Circuit’s decision is reported at 694 F.3d 1311. The case is commonly cited in connection with the statutory limits governing judicial challenges to USPTO patent-term-adjustment calculations and the treatment of agency determinations under § 154(b).

The legal significance was narrower than an infringement judgment. The court did not determine infringement, validity, damages, or a right to exclude a generic manufacturer. Instead, the litigation addressed the duration of the patent term itself.

How did Wyeth affect the Arius Two litigation?

Wyeth changed the economic and procedural environment for Arius Two. Before Wyeth, the USPTO’s interpretation generally prevented an applicant from receiving the full benefit of separate A-delay and B-delay periods when both occurred during the same prosecution history.

The Federal Circuit rejected that approach. It held that the statute required:

1. Calculation of the A-delay period.
2. Calculation of the B-delay period.
3. Addition of those periods.
4. Subtraction of the actual overlap between them.

The agency’s prior formula treated the two categories as mutually exclusive in circumstances where the statute did not require that result. Wyeth therefore increased the potential term of many patents that experienced both delayed examination and prosecution beyond the three-year period.

Arius Two’s action was commercially relevant because a corrected PTA calculation could extend the enforceable life of a patent beyond the term printed on the original patent record.

Was Arius Two a Paragraph IV or generic litigation case?

No. Arius Two was not a Hatch-Waxman action.

There was no:

• Abbreviated New Drug Application challenger;
• Paragraph IV certification;
• 30-month stay;
• ANDA-based infringement claim under 35 U.S.C. § 271(e)(2);
• generic manufacturer settlement;
• launch-at-risk dispute; or
• district-court judgment concerning pharmaceutical patent validity.

The defendant was the USPTO Director, not a generic company. The case therefore does not establish generic-entry timing for a marketed drug.

What was the FDA and Orange Book status?

Arius Two v. Kappos had no direct FDA or Orange Book component. The case did not challenge:

• FDA approval;
• New Chemical Entity exclusivity;
• five-year Hatch-Waxman exclusivity;
• three-year clinical-investigation exclusivity;
• pediatric exclusivity;
• orphan-drug exclusivity;
• REMS requirements;
• Orange Book listing;
• therapeutic-equivalence coding; or
• a reference-listed drug’s patent certification.

Any commercial effect would arise indirectly through the additional life of the Arius patent, assuming the patent covered a product, method, or technology with meaningful market value.

What patent-term issues did the case raise?

USPTO delay

The case implicated the statutory right to additional patent term for certain USPTO delays. A patent applicant may receive PTA for agency failures to meet statutory examination deadlines, subject to the statutory exclusions and applicant-delay reductions.

Three-year pendency

The B-delay provision is triggered when the USPTO fails to issue a patent within three years after the relevant filing date, subject to exclusions for certain prosecution events. The Wyeth methodology made this category particularly important for applications with long prosecution histories.

Overlap

The central calculation question was whether A-delay and B-delay periods overlapped. The Federal Circuit’s Wyeth framework requires the USPTO to identify the actual overlapping days rather than eliminate one entire category.

Applicant delay

Patent-term adjustment can be reduced by applicant conduct, including failure to engage in reasonable efforts to conclude prosecution. The calculation therefore depends on the complete prosecution record, including responses, amendments, extensions, requests for continued examination, appeals, and other filings.

How strong was the litigation position?

Arius Two’s legal position was strengthened by the Federal Circuit’s controlling decision in Wyeth. The principal merits issue had already been resolved favorably for patent owners. The remaining issues were generally case-specific:

• whether the action was timely;
• the correct patent and issue date;
• the amount of A delay;
• the amount of B delay;
• the periods of overlap;
• applicant-delay deductions;
• the scope of the court’s review; and
• whether the USPTO had correctly implemented the recalculation.

The case was therefore stronger on the statutory interpretation issue than on the amount of term available for the individual Arius patent. The business value depended on the patent’s claims, remaining life, product coverage, and enforceability.

Did the case establish patent expiration dates?

No. The litigation did not create a generally applicable expiration date for Arius patents or pharmaceutical products. A corrected PTA calculation must be determined patent by patent.

A patent’s effective expiration date generally requires combining:

• the statutory patent term under 35 U.S.C. § 154(a);
• any PTA under § 154(b);
• any patent-term extension under 35 U.S.C. § 156;
• terminal disclaimers;
• disclaimers filed during prosecution;
• maintenance-fee status; and
• any post-grant or judicial changes affecting enforceability.

A PTA award does not override a terminal disclaimer. Where a patent is subject to a terminal disclaimer, the disclaimer may cap the enforceable term even if the patent record otherwise reflects additional adjustment.

What was the commercial impact of Arius Two?

The commercial impact was potentially meaningful but patent-specific. Additional patent days can affect:

• licensing negotiations;
• royalty duration;
• freedom-to-operate assessments;
• product launch planning;
• patent portfolio valuation;
• enforcement strategy; and
• the timing of competitor entry.

The value of a PTA correction is highest when the patent covers a commercially important product or manufacturing process and when the corrected term falls near a planned competitor launch. The value is lower when the patent is expired, narrowed, terminally disclaimed, invalidated, nonessential to the product, or not connected to a regulated commercial product.

The docket does not establish a drug-specific revenue figure, generic-entry date, or licensing transaction. Those issues cannot be inferred from the PTA litigation alone.

How does Arius Two compare with Wyeth v. Kappos?

Issue	Arius Two v. Kappos	Wyeth v. Kappos
Type of proceeding	Patent-term-adjustment challenge	Patent-term-adjustment challenge
Defendant	USPTO Director	USPTO Director
Main legal issue	Review and application of PTA calculation rules	Interpretation of A/B delay overlap
Commercial subject	Arius patent term	Wyeth patents
Generic litigation	None	None
FDA dispute	None	None
Precedential importance	Applied the post-Wyeth framework in the Arius dispute	Established the controlling Federal Circuit interpretation
Primary business effect	Possible extension of enforceable patent life	Broader correction of USPTO PTA calculations

Wyeth supplied the principal substantive rule. Arius Two illustrates how a patent owner pursued judicial relief after the USPTO’s pre-Wyeth methodology produced a disputed term calculation.

Key Takeaways

• Arius Two v. Kappos, 1:10-cv-00225, was a USPTO patent-term-adjustment case.
• The litigation was not an ANDA, Paragraph IV, Orange Book, biosimilar, or patent-infringement action.
• The dispute arose from the USPTO’s calculation of A-delay and B-delay under 35 U.S.C. § 154(b).
• Wyeth v. Kappos materially strengthened the patent owner’s position by rejecting the USPTO’s prior treatment of overlapping A and B delay.
• The case did not establish a drug-specific patent expiration date or generic-launch date.
• Commercial value depended on the underlying Arius patent, its claims, remaining life, terminal disclaimers, and product relevance.
• PTA disputes require patent-specific review of the prosecution history and the USPTO’s delay calculations.
• The case has limited direct relevance to FDA exclusivity, Orange Book listings, biosimilar risk, or pharmaceutical settlement analysis.

FAQs

Did Arius Two involve a patent infringement claim?

No. It was an administrative review action concerning the USPTO’s calculation of patent-term adjustment.

Did Arius Two create a new patent term for Arius?

The case concerned correction of the USPTO’s calculation. Any additional term depended on the individual patent’s statutory adjustment, overlap periods, and applicant-delay deductions.

Was Arius Two connected to a pharmaceutical product?

The reported action does not establish an FDA-approved product, Orange Book-listed drug, or ANDA dispute. The case should not be treated as a pharmaceutical-launch decision without separate product and patent analysis.

Can Arius Two be cited in a patent-term-adjustment challenge?

Yes. The case is relevant to litigation over judicial review of USPTO PTA determinations, particularly in the post-Wyeth framework under 35 U.S.C. § 154(b).

Does a PTA correction eliminate a terminal disclaimer?

No. Patent-term adjustment does not automatically override a terminal disclaimer. The disclaimer must be analyzed separately when determining the enforceable expiration date.

References

1. Arius Two, Inc. v. Kappos, 694 F.3d 1311 (Fed. Cir. 2012).

2. U.S. Patent and Trademark Office. (2010). Manual of Patent Examining Procedure § 2735: Patent term adjustment under 35 U.S.C. § 154(b). U.S. Department of Commerce.

3. Wyeth v. Kappos, 591 F.3d 1364 (Fed. Cir. 2010).

4. United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.

5. United States Code. (2024). 5 U.S.C. §§ 701-706: Administrative Procedure Act judicial review.